Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 619
- Registration Number
- NCT05620836
- Locations
- 🇺🇸
Investigative Site US240, Scottsdale, Arizona, United States
🇺🇸Investigative Site US237, Scottsdale, Arizona, United States
🇺🇸Investigative Site US214, Arkansas, Arkansas, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
- Conditions
- Cutaneous Lichen Planus
- Interventions
- Drug: Vehicle cream
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT05593432
- Locations
- 🇺🇸
Northshore Medical Group Dermatology Skokie, Skokie, Illinois, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Dermassociates, Rockville, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT05593445
- Locations
- 🇺🇸
New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸UC Irvine, Irvine, California, United States
🇺🇸Circuit Clinical, West Seneca, New York, United States
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT05577182
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇧🇪Cliniques Universitaires Ucl Saint-Luc, Bruxelles, Belgium
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
- Conditions
- STAT1 Gain-of-Function Disease
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05561985
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
- Conditions
- Chronic Graft Vs. Host Disease
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05544032
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT05456529
- Locations
- 🇺🇸
Arlington Research Center, Arlington, Texas, United States
🇺🇸First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
- Conditions
- Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 82
- Registration Number
- NCT05429268
- Locations
- 🇹🇷
Ege University Hospital, Izmir, Turkey
🇧🇬Medical University Plovdiv, Plovdiv, Bulgaria
🇧🇬Acibadem Cityclinica Mhat Tokuda, Sofia, Bulgaria
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT05267106
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05253807
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States